Montefiore is one of only two hospitals in New York to receive designation as a Center of Excellence for CAR T-Cell Therapy by Kite Pharma, the manufacturer of the treatment.
We are now accepting patients for CAR T-cell therapy. Eligible patients are those receiving treatment for non-Hodgkin's lymphoma. We will also be accepting patients with acute lymphoblastic leukemia in the near future.
The ZUMA-1 study tested the use of CAR T-cells to treat relapse refractory lymphoma. Ira Braunschweig, MD, Director, Stem Cell Transplantation, and Clinical Program Director, Hematologic Malignancies, Montefiore Medical Center, served as the Principal Investigator for the study, and Montefiore was one of the only research sites in the Northeastern region to participate in the study. In total, six Montefiore patients have been treated with CAR T-cell therapy. The study shows that patients can successfully achieve remission with the treatment.